(New Date): Thursday, March 4, 11am GMT
Due to a scheduling conflict, iVom #6 has been postponed to Thursday, March 4 at 11:00 AM GMT
Phages (in)action in the gut
Since a decade we are studying how virulent phages target bacterial cells within the intestinal tract of mammals using different murine models. I will briefly reviewed what we learned about phage-bacteria interactions in the gut and how this knowledge can help understanding these dynamics in relation to human health.
A study that went wrong- phage engineering and phage pharmacokinetics
Details to come.
Phage therapy experience in France in the field of Bone and Joint infection
Phage therapy has been historically used to treat patients with bone and joint infections, with contradictory results. As bacteriophages have anti-biofilm effect, they are nevertheless promising to treat such infections, especially in the era of antimicrobial resistance. Since 2017, we implemented a multidisciplinary group dedicated to phage therapy for patients with complex bone and joint infection. We found that phage therapy has the potential to keep the function in patients with severe relapsing prosthetic joint infection. Based on our experience, identifying relevant clinical indications (such as prosthetic joint infection), and having multidisciplinary approach with international academic collaborations and interactions with national health authority and industry, are essential to go ahead and develop phage therapy in a close future.